Clinical Trials Browser

Recruiting × OTHER × lazertinib × Clear all

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic

NCT06268210 2026-02-09

NeoLazer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung